These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29435359)

  • 1. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
    Fleischmann R; Wollenhaupt J; Takiya L; Maniccia A; Kwok K; Wang L; van Vollenhoven RF
    RMD Open; 2017; 3(2):e000491. PubMed ID: 29435359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
    Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
    Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
    J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
    Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
    Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
    Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
    Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
    Mueller RB; Schulze-Koops H; Furst DE; Cohen SB; Kwok K; Wang L; Killeen T; von Kempis J
    Clin Rheumatol; 2022 Apr; 41(4):1045-1055. PubMed ID: 34973077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
    Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
    Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
    Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
    Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
    Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
    Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.
    Pope JE; Keystone E; Jamal S; Wang L; Fallon L; Woolcott J; Lazariciu I; Chapman D; Haraoui B
    ACR Open Rheumatol; 2019 Apr; 1(2):73-82. PubMed ID: 31777783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
    Haraoui B; Khraishi M; Choquette D; Lisnevskaia L; Teo M; Kinch C; Galos C; Roy P; Gruben D; Woolcott JC; Vaillancourt J; Sampalis JS; Keystone EC;
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):240-251. PubMed ID: 35678771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies.
    van der Heijde D; Landewé RBM; Wollenhaupt J; Strengholt S; Terry K; Kwok K; Wang L; Cohen S
    Rheumatology (Oxford); 2021 Apr; 60(4):1708-1716. PubMed ID: 33057725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
    Fleischmann R; Wollenhaupt J; Cohen S; Wang L; Fan H; Bandi V; Andrews J; Takiya L; Bananis E; Weinblatt ME
    Rheumatol Ther; 2018 Jun; 5(1):203-214. PubMed ID: 29417430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
    Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
    Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
    Genovese MC; van Vollenhoven RF; Wilkinson B; Wang L; Zwillich SH; Gruben D; Biswas P; Riese R; Takiya L; Jones TV
    Arthritis Res Ther; 2016 Jun; 18():145. PubMed ID: 27334658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
    Dikranian AH; Gonzalez-Gay MA; Wellborne F; Álvaro-Gracia JM; Takiya L; Stockert L; Paulissen J; Shi H; Tatulych S; Curtis JR
    RMD Open; 2022 May; 8(1):. PubMed ID: 35577477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.